Literature DB >> 165504

Tumor-inhibiting properties of the neutral P-O-ethyl ester of adenosine 3':5'-monophosphate in correlation with its crystal and molecular structure.

F A Cotton, R G Gillen, R N Gohil, E E Hazen, C R Kirchner, J Nagyvary, J P Rouse, A G Stanislowski, J D Stevens, P W Tucker.   

Abstract

The P-O-ethyl ester of cAMP has been synthesized, its inhibition of solid and ascites tumors studied, and its pattern of urinary excretion followed. Et-cAMP is more effective than cAMP against solid sarcoma 180 in mice and against Ehrlich ascites carcinoma cells in tissue culture. The urinary excretion pattern of injected E-t-cAMP suggests that about two-thirds of the injected dose (13 mumol per animal) is retained in the rat rather than being promptly excreted. Liver slice studies of the effect on glycogenolysis suggest that the Et-cAMP is converted to cAMP intracellularly. The compound crystallizes in space group P21 with one molecule per asymmetric unit. The base ring has the anti conformation. The ethyl group is endo to the base ring and is axial in the flattened chair-conformer six-membered ring formed by the 3'-5' O-P-O cyclization. In most other respects the structure of the compound is closely similar to the known structures of other cyclic nucleotides.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 165504      PMCID: PMC432528          DOI: 10.1073/pnas.72.4.1335

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  21 in total

1.  Phosphorus assay in column chromatography.

Authors:  G R BARTLETT
Journal:  J Biol Chem       Date:  1959-03       Impact factor: 5.157

2.  Derivatives of cyclic 3',5'-adenosine monophosphate.

Authors:  T POSTERNAK; E W SUTHERLAND; W F HENION
Journal:  Biochim Biophys Acta       Date:  1962-12-17

Review 3.  The chemistry and biological properties of nucleotides related to nucleoside 3',5'-cyclic phosphates.

Authors:  L N Simon; D A Shuman; R K Robins
Journal:  Adv Cyclic Nucleotide Res       Date:  1973

4.  Molecular conformation of guanosine 3,'5-cyclic monophosphate.

Authors:  A K Chwang; M Sundaralingam
Journal:  Nat New Biol       Date:  1973-08-01

Review 5.  Possibilities for drug development based on the cyclic AMP system.

Authors:  M S Amer; G R McKinney
Journal:  Life Sci       Date:  1973-10-01       Impact factor: 5.037

Review 6.  Clinical studies and applications of cyclic nucleotides.

Authors:  F Murad
Journal:  Adv Cyclic Nucleotide Res       Date:  1973

7.  Inhibition of tumor growth by nucleoside cyclic 3'-5'-monophosphates.

Authors:  D Gericke; P Chandra
Journal:  Hoppe Seylers Z Physiol Chem       Date:  1969-11

8.  Effects of some hormonal and other factors on the excretion of guanosine 3',5'-monophosphate and adenosine 3',5'-monophosphate in rat urine.

Authors:  J G Hardman; J W Davis; E W Sutherland
Journal:  J Biol Chem       Date:  1969-12-10       Impact factor: 5.157

9.  A protein binding assay for adenosine 3':5'-cyclic monophosphate.

Authors:  A G Gilman
Journal:  Proc Natl Acad Sci U S A       Date:  1970-09       Impact factor: 11.205

10.  Stereochemistry of nucleic acids and their constituents. XXVII. The crystal structure of 5'-methyleneadenosine 3',5'-cyclic monophosphonate monohydrate, a biologically active analog of the secondary hormonal messenger cyclic adenosine 3',5-monophosphate. Conformational "rigidity" of the furanose ring in cyclic nucleotides.

Authors:  M Sundaralingam; J Abola
Journal:  J Am Chem Soc       Date:  1972-07-12       Impact factor: 15.419

View more
  2 in total

1.  X-ray structure of cytidine-5'-O-dimethylphosphate. Novel stacking between the ribosyl O(2') hydroxyl oxygen atom and the base.

Authors:  R G Brennan; N S Kondo; M Sundaralingam
Journal:  Nucleic Acids Res       Date:  1984-09-11       Impact factor: 16.971

Review 2.  Fibrolamellar Hepatocellular Carcinoma: Mechanistic Distinction From Adult Hepatocellular Carcinoma.

Authors:  Kevin M Riggle; Rigney Turnham; John D Scott; Raymond S Yeung; Kimberly J Riehle
Journal:  Pediatr Blood Cancer       Date:  2016-03-14       Impact factor: 3.167

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.